Travere Therapeutics, Inc.
TVTX
$14.50
$1.017.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 233.18M | 203.45M | 177.64M | 155.72M | 145.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.18M | 203.45M | 177.64M | 155.72M | 145.24M |
| Cost of Revenue | 225.24M | 224.93M | 233.50M | 245.06M | 256.44M |
| Gross Profit | 7.94M | -21.48M | -55.86M | -89.33M | -111.20M |
| SG&A Expenses | 264.12M | 258.21M | 260.39M | 263.82M | 265.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 554.56M | 548.34M | 559.10M | 574.08M | 521.98M |
| Operating Income | -321.39M | -344.89M | -381.45M | -418.35M | -376.74M |
| Income Before Tax | -320.51M | -348.70M | -383.09M | -415.39M | -376.11M |
| Income Tax Expenses | 120.00K | 260.00K | 356.00K | 336.00K | 223.00K |
| Earnings from Continuing Operations | -320.63 | -348.96 | -383.45 | -415.73 | -376.33 |
| Earnings from Discontinued Operations | -915.00K | -2.50M | 237.54M | 254.60M | 264.93M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -321.55M | -351.45M | -145.91M | -161.13M | -111.40M |
| EBIT | -321.39M | -344.89M | -381.45M | -418.35M | -376.74M |
| EBITDA | -277.83M | -303.94M | -340.27M | -376.56M | -338.21M |
| EPS Basic | -4.10 | -4.56 | -1.88 | -2.09 | -1.60 |
| Normalized Basic EPS | -2.54 | -2.72 | -3.02 | -3.30 | -3.08 |
| EPS Diluted | -4.10 | -4.56 | -1.88 | -2.09 | -1.60 |
| Normalized Diluted EPS | -2.54 | -2.72 | -3.02 | -3.30 | -3.08 |
| Average Basic Shares Outstanding | 315.52M | 308.89M | 307.42M | 305.92M | 296.96M |
| Average Diluted Shares Outstanding | 315.52M | 308.89M | 307.42M | 305.92M | 296.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
